Functional MRI in awake-behaving primates is an emerging tool for bridging the gap between human fMRI and neurophysiology information from nonhuman primates. We report the use of magnetite dextran nanoparticles (Feridex) as a blood-pool agent to enhance fMRI contrast-to-noise (CNR) in primate FMRI. The intravascular half-life of the magnetite dextran was long compared to lanthanide chelates (T 1a2 198 min) with shortened T 2 relaxation observed in blood and cerebral cortex. Greater than 3-fold enhancement in the percentage MR signal change was observed using nanoparticles (13%) compared with conventional BOLD fMRI (4%). The calculated regional cerebral blood volume in macaque primary visual cortex increased 32% with photic stimulation. The increased CNR allows greater¯exibility in the design of awake-behaving primate fMRI studies with the potential for improvements in resolution and signi®cantly shortened imaging times.
INTRODUCTION
fMRI is a rapidly emerging tool in the study of primate physiology. Previous studies have addressed the potential value of fMRI in awake macaque monkeys for investigating visual neuroscience [1±5] and basal ganglia function [6] . One major limitation in performing monkey fMRI at 1.5 T is the limited signal-to-noise and consequently low contrast-to-noise ratio (CNR) from blood oxygen leveldependent (BOLD) contrast. As with all imaging techniques, there is a compromise between resolution and sensible imaging time. Monkeys are challenging subjects to study. They need to be trained meticulously to remain still for awake MRI studies (thus shorter imaging sessions facilitate behavioral compliance). However, the brain of a macaque monkey is approximately one-®fth of the size of a human brain [7] , so there is also a need for higher resolution than in human fMRI studies. One approach to this has been to do macaque imaging at higher applied magnetic ®eld [3] . While improving the CNR, this also increases the unfavorable susceptibility gradients and artifacts, which scale proportionately with the applied magnetic ®eld. Another approach has been to restrict imaging to anesthetized animals. This allows longer imaging times and reduces movement artifacts, but may also diminish BOLD effect due to the vasodilator effects by anesthetic agents, and consequent changes on cerebral blood¯ow (CBF) [8] . The use of anesthesia also excludes cognitive studies for which awake-behaving subjects are required.
We investigated the effect of a blood-pool T 2 contrast agent (i.e. a cerebral blood volume (CBV) technique) on CNR compared with conventional BOLD contrast in awake-behaving primate fMRI experiments. Previous studies have demonstrated the utility of such agents for MRI in rats [9] , cats [10] and human subjects [11] .
The use of contrast agents has not found much favor in human cognitive studies because this makes the study more invasive, but holds promise for awake animal studies [12] . This is the ®rst time this technique has been applied to awake primate imaging. Techniques that employ a T 2 contrast agent provide images sensitive to changes in regional CBV. This has been shown in rats to change by 20% with neural activation [9, 13] and by 25% [11] to 32% [14] in humans. Unlike deoxyhemoglobin susceptibility, the CBV change is not dependent on applied magnetic ®eld [9] , and thus this technique provides great scope for improved fMRI contrast even at conventional magnetic ®elds (1.5 T).
MATERIALS AND METHOD
Animal subjects: Approval for this research was obtained from The Institutional Animal Care and Use Committee, Epidemiology and Biosafety Committees. All imaging was done on a 1.5 T Siemens Vision MR scanner with 23 mT/m gradients (300 ìs rise time). Awake-behaving studies were done on a 8.5 kg male rhesus macaque monkey (Macaca mulatta) lying in a sphinx position within this scanner using a 19 cm circularly polarized knee coil. Contrast excretion measurements were done outside the MR scanner on the same animal. Relaxometry studies were also performed on this monkey and on two additional male macaque monkeys (5.5 kg and 10.5 kg) under iso¯urane anesthesia. The technique has been described previously [1, 2] . In brief, the animal was transported to the MRI facility in a custom-designed cage. For awake studies he crawled into a short tube so that his legs were accessible for i.v. administration of T 2 contrast agent. The monkey was trained to present his leg to the animal handler and accept an intravascular line into a saphenous vein without sedation or general anesthesia. The monkey then crawled into a larger tube which was transferred to the MRI scanner. The monkey's head was secured to the transmit/ receive coil and a screen placed 57.3 cm in front of him (providing a AE 228 visual ®eld of view). Eye-position tracking was performed using a custom-built shielded video camera placed at the bore of the scanner, which was sensitive in the infrared range, and eye illumination from a circular array of 28 MRI compatible IR light-emitting diodes emitting at 810 nm [15] . Digital signal processing involved a system from ISCAN (Iscan Inc. Cambridge, MA) integrated into a computer running a custom program written with Labview software (National Instruments Corporation, Austin, TX). This set-up allowed eye tracking in complete darkness to an accuracy of within 18 of arc. The animal was trained to remain motionless in the scanner for the duration of the imaging experiment (i.e. while gradient noise was audible) and to ®xate on a central ®xation point to an accuracy of , 48 visual angle for the duration of the stimulus. He was given a fruit juice reward at the end of each imaging run.
For anesthetized studies, the animal was sedated with 10 mg/kg ketamine and maintained on 2% iso¯urane using an anesthetic set-up modi®ed for MRI compatibility.
Contrast agent:
For functional imaging studies with T 2 contrast agent we used magnetite dextran nanoparticles (Feridex, Advanced Magnetics Inc, Cambridge, MA) infused i.v. This was given as 4.2 mg Fe/kg (75 ìmol/kg) diluted into 25 ml and infused over 5 min through a 5 ìm ®lter. Imaging was started within 10 min of completing the infusion (ensuring equilibrium state concentration). For assessment of whole blood clearance, a dose of 2.8 mg Fe/ kg (50 ìmol/kg) was used.
MR imaging: BOLD and magnetite-enhanced functional images were acquired using a gradient-echo echo planar imaging (GE-EPI) mosaic sequence. [2] . Relaxometry measurements on in vitro venous blood were performed using a CPMG spectroscopy sequence on a Bruker minispec mq60 at 60 Mhz (Bruker Analytik GmbH, Rheinsteffen, Germany).
Stimulus paradigm: The stimulus consisted of a 6 s black and white polar checker-board alternating at 8 Hz, which subtended a visual angle of AE208. The stimulus was preceded by a 18 ®xation point visible for 8 s. Following the ®xation dot and checker-board stimulus, the animal remained in the dark for a further 76±106 s to allow acquisition of the full recovery of the hemodynamic response.
Image post-processing: Functional imaging data using BOLD and magnetite dextran contrast were analyzed offline using AFNI software running on a Unix workstation [16] . Functional images were co-registered using a volumeregistration algorithm under AFNI. A weighted linear least squares ®t of the images was employed with Fourier interpolation used for resampling [17] . Images with excessive motion artifact not corrected by the registration algorithm were excluded. The remaining runs were averaged together to create a single dataset for BOLD imaging and a single dataset for magnetite-enhanced imaging. A representative region of interest was chosen in primary visual area V1 (Fig. 1) . The time course of the percentage change in MRI signal in this volume was plotted for BOLD and magnetite-enhanced fMRI (Fig. 2) .
For cerebral relaxometry measurements following magnetite dextran infusion, regions of interest were drawn around anatomically de®ned gray matter using Scion Image software (http://www.scioncorp.com). R 2 Ã transverse relaxation rate was calculated by assuming an exponential relationship between the MR signal (S(TE)), the echo time (TE), and the initial signal (S(0)) described by eqn 1:
The ®t optimization was implemented in Matlab (The Mathworks Inc., Natick, MA) using a proprietary largescale subspace trust-region algorithm based on an interior re¯ective Newton method [18] . The algorithm allows speci®cation of upper and lower bounds on each optimized parameter. Relaxivity data on whole blood to assess clearance of contrast media was assumed to follow ®rst order kinetics and was modeled with monoexponential decline described by eqn 2:
[Fe] blood is the concentration of Fe in blood, C 0 is the instantaneous concentration at time zero. Dividing the injected dose by the instantaneous concentration of contrast media, C 0 , yields the volume of distribution of the agent within the animal. The constant, b, is an excretion constant from which the half-life of elimination from blood can be calculated. There is a linear relationship between the transverse relaxation rate of the magnetite dextran contrast media in blood and the concentration of Fe. The main components of the measured R 2 Ã are components from blood itself, R 2 Ã blood , and from erogenous magnetite, R 2 Ã Fe (eqn 3):
The unknown contribution to transverse relaxation rate from Fe, R 2 Ã Fe , used in eqn 3, was calculated by making serial dilutions of a known concentration of Feridex with water as described in eqn 4 ( Fig. 3a) :
Using eqns 3 and 4, the actual concentration of Fe was quanti®ed from measurements of R 2 Ã for whole blood drawn at regular intervals following injection of the contrast agent (Fig. 3b) .
To compare the magnitude, duration and onset delay of the positive MR signal change for BOLD with the negative signal change for magnetite-enhanced fMRI, the data were ®tted to a gamma-variate function of the form in equation 5 using the same Matlab routine described above:
A, r, and a are ®t constants and t 0 de®nes the onset delay following the neuronal stimulus. The maximum signal change was the peak of the curve. The duration of activity was compared during the period when the MR signal exceeded 10% of its maximal value. We calculated the percentage change in the regional CBV following photic stimulation. This model assumes that the effect of the decreased transverse relaxation rate due to BOLD is negligible compared to the increase due to CBV changes with the intravascular contrast agent. Previous studies have shown the rate of change in transverse relaxation rate with blood iron concentration is proportional to the CBV (i.e. the cerebral blood volume CBV(t) can be calculated from the slope of a plot of R 2 Ã change with [Fe] blood [11] ), as described in eqn 6: (0) is the blood concentration of Fe due to magnetite dextran prior to injection (i.e. zero) and K is a proportionality constant. The fractional change in blood volume following photic stimulation, ÄCBV, can thus be calculated from the CBV during rest, CBV(r), and during activation, CBV(a), from eqn 7:
From eqn 1, this can be written in terms of the ratio of MR signal during photic stimulation and at rest:
R 2 Ã in brain was measured before injection of magnetite dextran, R 2 Ã (pre), and at regular time points during the experiment, R 2 Ã (t). This value of R 2 Ã (t) was interpolated to the actual time point of the photic stimulation measurement, R 2 Ã (r), to allow for changes in R 2 Ã due to hepatic elimination of Fe (see eqn 2). The MR signal change, S(t), following photic stimulation was ®tted to the gammavariate function described by eqn 5 (Fig. 2) . S(r) was the value of the function at t , 5 s and S(a) was the maximum value of the function (t 44 s).
RESULTS
Nine runs of BOLD contrast and ®ve runs of magnetiteenhanced contrast, which were free from any motion artifact, were acquired in an awake-behaving monkey with eye traces con®rming he was ®xating for the duration of the experiment. The distribution of fMRI activation for the checker-board stimulus is seen in visual cortex in the correlation map in Fig. 1 . The hemodynamic response curves for conventional BOLD fMRI and magnetite-enhanced fMRI are shown in Fig. 2 . The positive BOLD effect and negative magnetite-induced MR signal changes were ®tted to independent gamma-variate functions. Following photic stimulation, the MR signal in macaque visual cortex is modulated by up to 4% for BOLD imaging and follows a characteristic time course similar to that routinely described in human fMRI at 1.5 T. Increase in BOLD MR signal occurred in primary visual cortex almost immediately following stimulus onset. The peak BOLD signal change was observed 10 s following the stimulus onset. The response showed a typical rise followed by an undershoot, returning to baseline by 50 s. The duration of the positive BOLD change (measured between the rise above 10% maximum signal change, to the fall below 10% maximum) was 22 s (1±23 s after stimulus onset). Using i.v. magnetite dextran, there is a 13.1% negative MR signal change in the same area of primary visual cortex following photic stimulation. Maximum effect was seen at 44 s. The modulation in MR signal persisted for 90 s (15±105 s between the 10% of maximum points). The intravenous magnetite dextran, increased the R 2 Ã (and R 2 ) relaxation rates in resting gray matter. The change in transverse relaxation rate of blood over time was measured in the same animal used for the fMRI study, and is presented in Fig. 3b . This shows an elimination T 1a2 from blood of 198 min. The volume of distribution (instantaneous blood concentration divided by dose injected) was 825 ml. The percentage change in regional cerebral blood volume in macaque primary visual cortex following photic stimulation was 32%.
DISCUSSION
Feridex (ferumoxide solution) is an aqueous colloid of magnetite iron oxide nanoparticles (60±150 nm diameter) associated with dextran having an average chemical composition of FeO 1X44 . Excretion of Feridex is 98% hepatic (its primary use in diagnostic imaging is as a T 2 liver contrast agent). In this study we have used it as a blood-pool contrast agent, taking advantage of its slow excretion kinetics and prolonged blood half-life. The blood volume of a 8.5 kg macaque monkey is $10% of body weight [19] , thus the calculated volume of distribution (825 ml) con®rms that Feridex is a true blood-pool agent. fMRI provides an indirect map of neuronal activation by demonstrating changes in cerebral blood dynamics that accompany neural activity. These temporally correlated changes may be seen as changes in blood¯ow [20] , blood volume [14] or changes in the deoxygenation of hemoglobin [21] . Imaging the changes in blood volume is well established: the ®rst fMRI descriptions of neuronal activity in humans mapped changes in CBV [14] . For human studies, it has become more popular to use fMRI studies with endogenous contrast based on changes in the oxygenation of hemoglobin thus making the study entirely noninvasive. The use of iron oxide T 2 contrast agents with a long i.v. half-life has been shown to be a valid method to track CBV changes during neuronal stimulation in rats [9] and human subjects [11] . The increase in transverse relaxation rate (ÄR 2 Ã 1/ÄT 2 Ã ) due to increased blood volume competes with the decrease in relaxation rate due to changes in deoxyhemoglobin accompanying neuronal activation. It is necessary to use a suf®cient intravascular concentration of contrast agent to ensure that the signal changes induced by the contrast agent and increased CBV dominate concurrent BOLD changes. At 1.5 T these relax-ivity changes due to hemoglobin susceptibility effects are relatively small; however the observed MR signal changes due to the T 2 agent are less than the theoretical maximum, as these competing effects reduce the magnitude of the MR signal change [9] . The calculated CBV change with stimulation was 32%. This is in good agreement with previous measurements of between 25% [11] and 32% [14] in human subjects. This concordance in CBV changes between human and macaque highlights a similarity in their neurovascular physiology which underscores the value of macaque fMRI as a model for better understanding human neurophysiology.
It is important to consider the decay in R 2 Ã over time due to hepatic elimination of contrast medium as well as the R 2 Ã modulation due to changes in blood volume. The elimination half-life of Feridex (198 min) is of the same order of magnitude as the duration of many primate physiology studies. Closer inspection of the intravascular iron concentration during a typical 3.5 h primate imaging session using a dose of 4.2 mg Fe/kg (75 ìmol/kg) shows it ranged from 36.75 ìg Fe/ml (659 ìM) instantaneously following injection to 19.5 ìg Fe/ml (350 ìM). Comparison with previous studies using the same T 2 contrast agent in humans indicates that the BOLD effect due to auditory stimulation is completely negated by the iron-oxide enhanced CBV effect at a concentration of 8.4 ìg Fe/ml (150 ìM) [11] . Extrapolating our elimination curve (Fig. 3) to this point where the BOLD effect completely opposes signal due to exogenous magnetite, indicates that signal would be lost 7 h after injection. During prolonged studies, the contrast concentration will diminish, and the opposing BOLD effect will reduce the MR signal, causing reduced CNR and greater variability. During a typical primate study, the opposing effects on transverse relaxation from BOLD may be assumed to be negligible. Under ideal conditions, the signal change with neuronal stimulation could re¯ect the whole 32% increase in CBV, thus CNR improvements of 8-fold could theoretically be achieved over our 4% BOLD MR signal change. There is thus scope to improve the MR signal response above the 3-fold enhancement demonstrated here. The use of higher doses is under review. Our TE of 50 ms was initially set for maximum tissue contrast during BOLD studies, and was held constant during the study. Reducing the TE to the T 2 Ã of grey matter following magnetite dextran infusion would further improve SNR and the CNR observed during magnetite-enhanced fMRI. Additionally, using other iron oxide agents with smaller particle size than Feridex (and a longer elimination half-life and higher T 2 relaxivity characteristics [22] ) would further improve the signal bene®t over conventional BOLD imaging. The variability of the MR signal change in Fig. 2 is larger for magnetite-enhanced fMRI than for BOLD. This is due to reduction of the resting MR signal by the addition of magnetite dextran. Magnetite reduces the T 2 Ã of tissue, and thus measured signals for a given TE are lower. The resting MR signal is approximately halved by the addition of magnetite dextran, thus decreasing the SNR. In non-human primates, the temporal dynamics of the CBV changes are slower than the BOLD effect (similar to that described in rats [9] ). This may place some constraints on paradigm design. For block design paradigms, the timecourse of each state may need to be longer than the minimum times typically possible for BOLD studies, however superposition calculations may be used to reduce this increase in experimental time. The use of event-related techniques (currently used in BOLD fMRI to observe temporal changes which are fast relative to the prolonged hemodynamic response [23] ) can potentially be applied to CBV imaging as well. The prolonged HRF using magnetite also needs to be considered when directly comparing fMRI with primate electrophysiology. The temporal resolution of MRI is already several orders of magnitude longer than that achievable with single electrode recordings. The advantages of functional MRI is the superior spatial resolution it affords, thus the potential for added CNR (and hence spatial resolution) are likely to outweigh any loss in temporal resolution from CBV techniques. For most primate studies, the 3-fold increase in CNR (with theoretically further increase possible) outweighs many limitations that the slower return to baseline may place on the choice of paradigm. To achieve a comarable 3-fold increase in CNR using BOLD fMRI at 1.5 T would require a 9-fold increase in experiment time or 3-fold increase in voxel size.
The added CNR by using magnetite-enhanced fMRI can be used to improve resolution or shorten total experimentation time. Motion artifact is the major dif®culty in imaging awake-behaving primates, and the ability to reduce the number of runs (and the overall length of an experiment) will have dramatic and positive bene®ts on experimental success. Non-human primate functional neuroanatomy has been used as a model for better understanding the human brain. The smaller brain size may equate to smaller functional units within the cortex for which higher resolution is required (although the exact scaling factor of functional units across species remains to be determined [24] ). The ability to achieve higher resolution in primate fMRI also adds to its utility when comparing with neurophysiology data.
The BOLD effect scales between linearly and quadratically with applied ®eld strength [25] . Thus high ®eld imaging at 4.7 T [3] could be expected to afford at least a 3-fold increase in CNR. This theoretical gain needs to be offset by increased bulk-susceptibility artifacts at higher applied magnetic ®elds. Using magnetite-enhanced fMRI for primate imaging at 1.5 T allows a comparable increase in CNR (with further CNR improvement anticipated with the use of alternate contrast agents), but without the increase in bulk susceptibility distortions induced by higher ®eld. Similar improvements in resolution seen by increasing the applied ®eld strength to 4.7 T are thus achievable using magnetite-enhanced fMRI at 1.5 T.
CONCLUSION
We describe a modi®cation of conventional BOLD fMRI applied to awake-behaving primates. Intravenous infusion of magnetite dextran nanoparticle T 2 contrast agent produces a 3-fold increase in CNR. Opportunities for further optimization are also discussed. Considerably faster overall experiments involving fewer sampling repetitions may now be performed, with the potential for higher resolution imaging compared with existing fMRI techniques at 1.5 T. Regional cerebral blood volume increases by 32% in macaque visual cortex, which is comparable to the neuron-ally induced vascular changes previously described in humans.
